TargetMol

Milveterol HCl

Product Code:
 
TAR-T33386
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33386-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33386-5mg5mg£328.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33386-10mg10mg£448.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33386-25mg25mg£691.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33386-50mg50mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33386-100mg100mg£1,243.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33386-500mg500mg£2,416.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Milveterol( GSK159797) is a long-acting β(2) -adrenergic receptor agonist for the potential treatment of chronic obstructive pulmonary disease (COPD).
CAS:
804518-03-4
Formula:
C25H31Cl2N3O4
Molecular Weight:
508.44
Pathway:
Neuroscience|GPCR/G Protein
Purity:
0.98
SMILES:
Cl.Cl.O[C@@H](CNCCc1ccc(NC[C@H](O)c2ccccc2)cc1)c1ccc(O)c(NC=O)c1
Target:
Adrenergic Receptor

References

Jacobsen JR, et al. A multivalent approach to the discovery of long-acting ?(2)-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett. 2012;22(2):1213-1218. Cazzola M, et al. Novel bronchodilators in asthma[J]. Current opinion in pulmonary medicine, 2010, 16(1): 6-12. Jacobsen JR, et al. Multivalent design of long-acting ?(2)-adrenoceptor agonists incorporating biarylamines. Bioorg Med Chem Lett. 2014;24(12):2625-2630. Montuschi P, et al. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58(10):4131-416